KPRX

SEC source: 0001104659-21-011852 · tm215262-10_4seq1.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,268

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.32 to $6.34, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-011853 · tm215262-11_4seq1.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,302

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.34 to $6.35, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-011851 · tm215262-9_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,746

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.34 to $6.42, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-011850 · tm215262-8_4seq1.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,331

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.34 to $6.35, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-011852 · tm215262-10_4seq1.xml · derivative · entry 2

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-02-01

F3 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-21-011849 · tm215262-7_4seq1.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2031-02-01

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022.

SEC source: 0001104659-21-011847 · tm215262-5_4seq1.xml · derivative · entry 1

CHANEY PAUL G · CIK 0001277477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2031-02-01

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022.

SEC source: 0001104659-21-011853 · tm215262-11_4seq1.xml · derivative · entry 2

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-02-01

F3 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-21-011851 · tm215262-9_4seq1.xml · derivative · entry 2

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-02-01

F3 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-21-011850 · tm215262-8_4seq1.xml · derivative · entry 2

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-02-01

F3 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-21-011848 · tm215262-6_4seq1.xml · derivative · entry 1

HANCOCK THOMAS · CIK 0001619727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2031-02-01

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022.

SEC source: 0001104659-21-011845 · tm215262-3_4seq1.xml · derivative · entry 1

GOLDBERG MORTON · CIK 0001619731 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2031-02-01

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022.

SEC source: 0001104659-21-011846 · tm215262-4_4seq1.xml · derivative · entry 1

MALFROY-CAMINE BERNARD · CIK 0001619732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2031-02-01

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022.

SEC source: 0001104659-21-011844 · tm215262-2_4seq1.xml · derivative · entry 1

Obermayr Franz · CIK 0001843571 · Acting CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-02-01

F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0000919574-21-000168 · ownership.xml · derivative · entry 4

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director · 10% owner

Boyd Steven · CIK 0001706140 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,531,101

Underlying: Common Stock · 0 shares

Expires 2025-01-06

F3 · kind: On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the "Warrants"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73.

F3 · price: On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the "Warrants"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73.

F1 · ownership.nature: The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.

F2 · ownership.nature: (Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000919574-21-000168 · ownership.xml · derivative · entry 3

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director · 10% owner

Boyd Steven · CIK 0001706140 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,531,101

Underlying: Common Stock · 1,531,101 shares

Expires 2025-01-06

F3 · kind: On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the "Warrants"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73.

F3 · price: On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the "Warrants"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73.

F1 · ownership.direct: The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.

F2 · ownership.direct: (Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000919574-21-000168 · ownership.xml · nonDerivative · entry 2

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director · 10% owner

Boyd Steven · CIK 0001706140 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,346,601

F1 · ownership.nature: The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.

F2 · ownership.nature: (Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000919574-21-000168 · ownership.xml · nonDerivative · entry 1

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director · 10% owner

Boyd Steven · CIK 0001706140 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,346,601

F3 · price: On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the "Warrants"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73.

F1 · ownership.direct: The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.

F2 · ownership.direct: (Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-21-000927 · tm211689-1_4seq1.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,256

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2021.

SEC source: 0001104659-21-000934 · tm211689-3_4seq1.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,613

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.84 to $4.85, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-000935 · tm211689-4_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,288

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $4.88, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-000932 · tm211689-2_4seq1.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,292

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $4.85, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-133326 · tm2038041-4_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,371

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020.

SEC source: 0001104659-20-133325 · tm2038041-3_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,993

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.76 to $3.80, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-133324 · tm2038041-2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,407

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020.

SEC source: 0001104659-20-133323 · tm2038041-1_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,728

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020.

SEC source: 0001104659-20-120954 · tm2034888d3_form4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,462

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2020.

SEC source: 0001104659-20-120955 · tm2034888d4_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,581

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2020.

SEC source: 0001104659-20-120953 · tm2034888d2_form4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,819

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2020.

SEC source: 0001104659-20-120949 · tm2034888d1_form4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,498

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2020.

SEC source: 0001104659-20-112300 · tm2032523-1_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,558

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.88 to $3.99, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-112303 · tm2032523-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,204

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.88 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-112302 · tm2032523-3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,595

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.88 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-112301 · tm2032523-2_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,916

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.88 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-102299 · tm2030216d3_form4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,656

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-102298 · tm2030216d2_form4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,693

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2020.

SEC source: 0001104659-20-102300 · tm2030216d4_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,835

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-102296 · tm2030216d1_form4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,014

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2020.

SEC source: 0001104659-20-090917 · tm2026743-1_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,753

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020.

SEC source: 0001104659-20-090920 · tm2026743-4_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,111

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020.

SEC source: 0001104659-20-090919 · tm2026743-3_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,463

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.12, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-090918 · tm2026743-2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,790

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020

SEC source: 0001104659-20-081219 · tm2024119-1_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,845

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2020.

SEC source: 0001104659-20-081227 · tm2024119-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,078

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2020.

SEC source: 0001104659-20-081225 · tm2024119-3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,885

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2020.

SEC source: 0001104659-20-081223 · tm2024119-2_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,206

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2020.

SEC source: 0001104659-20-069823 · tm2021837-2_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,939

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.11 to $5.1775, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-069826 · tm2021837-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,703

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.11 to $5.2202, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-069824 · tm2021837-3_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,303

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.11 to $5.1781, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-069822 · tm2021837-1_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,982

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.11 to $5.1781, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.